Carotid artery stenting outcomes: do they correlate with antiplatelet response assays?
| Autor: | Adnan H. Siddiqui, Kenneth V. Snyder, Jorge L. Eller, Maxim Mokin, Travis M. Dumont, Sabareesh K. Natarajan, Melissa S. Baxter, L. Nelson Hopkins, Michael M. Wach, Elad I. Levy, Grant C. Sorkin |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Ticlopidine medicine.medical_treatment Kaplan-Meier Estimate Brain Ischemia P2Y12 medicine Prevalence Humans Carotid Stenosis cardiovascular diseases Myocardial infarction Registries Prospective cohort study Stroke Aged Retrospective Studies Aged 80 and over Aspirin Cerebral Revascularization business.industry Stent Sequela General Medicine Middle Aged medicine.disease Clopidogrel Receptors Purinergic P2Y12 Treatment Outcome Anesthesia Surgery Female Stents Neurology (clinical) Drug Monitoring business Platelet Aggregation Inhibitors medicine.drug Follow-Up Studies |
| Zdroj: | Journal of neurointerventional surgery. 6(5) |
| ISSN: | 1759-8486 |
| Popis: | Objective Limited data exist regarding the use of antiplatelet response assays during neuroendovascular intervention. We report outcomes after carotid artery stenting (CAS) based on aspirin and P2Y12 assays. Methods We retrospectively identified patients who had aspirin and P2Y12 assays at the time of stenting. Aspirin (325 mg) and clopidogrel (75 mg) were started 7–10 days pre-intervention. If not possible, aspirin (650 mg) and clopidogrel (600 mg) loading doses were given pre-intervention. Assays were checked on postoperative day 0/1. Outcomes included neurological ischemic sequela at 30 days, 1 and 2 years, as well as 30 day death/hemorrhage/myocardial infarction. Results 449 patients were included. Mean P2Y12 reaction unit (PRU) values were higher in patients with an ipsilateral ischemic event (stroke/transient ischemic attack (TIA)) or stroke (alone) at 1 and 2 years than in patients with no events: ischemic event versus no event at 1 year, 252 vs 202 (p=0.008); stroke versus no stroke at 1 year, 252 versus 203(p=0.029); ischemic event versus no event at 2 years, 244 vs 203 (p=0.047); stroke versus no stroke at 2 years, 243 versus 203 (p=0.082). Ischemic event free survival (stroke/TIA, p=0.0268) and overall survival (p=0.0291) post-CAS were longer in patients with PRU ≤198 compared with an initial threshold of PRU ≤237. Mean PRU values were higher in patients who died from all causes at 30 days than in survivors (p=0.031). No correlation was found between lower PRU values and hemorrhage. Aspirin reaction units did not correlate with outcome. Conclusions PRU ≤198 may be associated with a lower incidence of ischemic neurological sequela and death post-CAS. Prospective studies are needed to validate the relationship between antiplatelet assays and outcomes post-CAS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|